Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer. (26th March 2012)

• Record Type: Journal Article
• Authors: Baba, Yuh; Fujii, Masato; Tokumaru, Yutaka; Kato, Yasumasa
• Other Names: Roach M. Academic Editor.
• Is Part Of: Journal of oncology. Volume 2012(2012)
• Publication Date: 2012-03-26
• Subjects: Oncology -- Research -- Periodicals; Tumors -- Periodicals; Neoplasms; Oncology -- Research; Tumors; Periodicals; Periodicals; 616.994
• DOI: 10.1155/2012/986725
• Languages: English
• ISSNs: 1687-8450

Abstract

Abstract : Although EGFR is expressed at high levels in head and neck squamous cell carcinomas (HNSCCs) and mutations are extremely rare, monotherapy with EGFR inhibitors has shown limited success. The PI3kinase/Akt pathway is responsible for cellular survival, and inhibition of phosphatidylinositol (PI) synthesis has antiproliferative, anti-invasive, and antiangiogenesis effects on HNSCC. Molecular crosstalk has been observed between EGFR and IGF1R signaling through the PI3kinase/Akt pathway in HNSCC, as has molecular crosstalk between the NF κ B and STAT3 signaling pathways. Therefore, the combination of an EGFR antagonist with an agent that inhibits the activation of both Akt and NF κ B may overcome resistance to EGFR antagonists in HNSCC.